ASX RELEASE 30th November 2021

Paradigm Investor Webinar

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (Paradigm or the Company), a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, is pleased to announce it will hold an investor webinar on **Thursday 2 December 2021 at 12:30pm AEDT** with Chairman Paul Rennie, interim CEO Dr Donna Skerrett and CFO Justin Cahill.

The webinar will discuss:

- Phase 3 clinical program for Osteoarthritis
- Commercial strategy

Please register for the webinar at the following link:

https://us02web.zoom.us/webinar/register/WN_KOCJGv7tRkuqsO5q_vbN3Q

Investors are invited to send questions prior to the webinar to investorrelations@paradigmbiopharma.com.

After registering, you will receive a confirmation email about joining the webinar. A recording will be available at the same link above shortly after the conclusion of the session.

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:
Simon White
Director of Investor Relations
Tel: +61 404 216 467
Paradigm Biopharmaceuticals Ltd
ABN: 94 169 346 963
Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA
Email: investorrelations@paradigmbiopharma.com